Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: A retrospective cohort study

The Lancet Infectious Diseases

Volumn 14, Issue 11, 2014, Pages 1090-1095

  Omrani, Ali S ^a   Saad, Mustafa M ^a   Baig, Kamran ^a   Bahloul, Abdelkarim ^a   Abdul Matin, Mohammed ^a   Alaidaroos, Amal Y ^a   Almakhlafi, Ghaleb A ^a   Albarrak, Mohammed M ^a   Memish, Ziad A ^b   Albarrak, Ali M ^a  

^a Prince Sultan Military Medical City   (Saudi Arabia)

^b ALFAISAL UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; RECOMBINANT PROTEIN;

AGED; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MIDDLE EAST; NEUTROPHIL COUNT; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEVERE ACUTE RESPIRATORY SYNDROME; TREATMENT OUTCOME; ADOLESCENT; ADULT; CORONAVIRUS INFECTIONS; DRUG EFFECTS; MIDDLE AGED; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; SAUDI ARABIA; SURVIVAL; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; COHORT STUDIES; CORONAVIRUS INFECTIONS; FEMALE; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; SAUDI ARABIA; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84908285527     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(14)70920-X     Document Type: Article

References (27)

1. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012, 367:1814-1820.
2. Severe respiratory disease associated with Middle East respiratory syndrome coronavirus (MERS-CoV)-11th update European Centre for Disease Prevention and Control, (accessed Sept 17, 2014). http://www.ecdc.europa.eu/en/publications/Publications/Middle-East-respiratory-syndrome-coronavirus-Saudi%20Arabia-Qatar-Jordan-Germany-United-Kingdom.pdf.
3. Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 2013, 13:752-761.
4. Omrani AS, Matin MA, Haddad Q, Al-Nakhli D, Memish ZA, Albarrak AM A family cluster of Middle East respiratory syndrome coronavirus infections related to a likely unrecognized asymptomatic or mild case. Int J InfectDis 2013, 17:e668-e672.
5. Assiri A, McGeer A, Perl TM, et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med 2013, 369:407-416.
6. Arabi YM, Arifi AA, Balkhy HH, et al. Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection. Ann Intern Med 2014, 160:389-397.
7. Clinical management of severe acute respiratory infections when novel coronavirus is suspected: what to do and what not to do WHO, (accessed June 12, 2014). http://www.who.int/csr/disease/coronavirus_infections/InterimGuidance:ClinicalManagement_NovelCoronavirus_11Feb13.pdf.
8. Clinical decision making tool for treatment of MERS-CoV v.1.1 Public Health England, International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC)International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC), (accessed June 14, 2014). http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317139281416.
9. Peiris JSM, Yuen KY, Osterhaus ADME, Stöhr K The severe acute respiratory syndrome. N Engl J Med 2003, 349:2431-2441.
10. Stockman LJ, Bellamy R, Garner P SARS: systematic review of treatment effects. PLoS Med 2006, 3:e343.
11. McCloskey B, Zumla A, Stephens G, Heymann DL, Memish ZA Applying lessons from SARS to a newly identified coronavirus. Lancet Infect Dis 2013, 13:384-385.
12. Momattin H, Mohammed K, Zumla A, Memish ZA, Al-Tawfiq JA Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)--possible lessons from a systematic review of SARS-CoV therapy. Int J Infect Dis 2013, 17:e792-e798.
13. Falzarano D, de Wit E, Martellaro C, Callison J, Munster VJ, Feldmann H Inhibition of novel beta coronavirus replication by a combination of interferon-alpha2b and ribavirin. Sci Rep 2013, 3:1686.
14. Falzarano D, de Wit E, Rasmussen AL, et al. Treatment with interferon-alpha2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med 2013, 19:1313-1317.
15. Corman VM, Muller MA, Costabel U, et al. Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections. Euro Surveill 2012, 17:20334.
16. Surveillance definitions for specific types of infections US Centers for Disease Control and Prevention National Healthcare Safety Network, (accessed June 14, 2014). http://www.cdc.gov/nhsn/pdfs/pscmanual/17pscnosinfdef_current.pdf.
17. Dellinger RP, Levy M, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intens Care Med 2013, 39:165-228.
18. Al-Tawfiq JA, Momattin H, Dib J, Memish ZA Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int J Infect Dis 2014, 20:42-46.
19. Khalid M, Al Rabiah F, Khan B, Al Mobeireek A, Butt TS, Al Mutairy E. Ribavirin and interferon (IFN)-alpha-2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus (MERS-CoV): a preliminary report of two cases.
20. de Wilde AH, Raj VS, Oudshoorn D, et al. MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-alpha treatment. J Gen Virol 2013, 94:1749-1760.
21. Hart BJ, Dyall J, Postnikova E, et al. Interferon-beta and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. J Gen Virol 2014, 95:571-577.
22. Chan JF, Chan KH, Kao RY, et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect 2013, 67:606-616.
23. Dyall J, Coleman CM, Hart BJ, et al. Repurposing of clinically developed drugs for treatment of Middle East Respiratory Coronavirus Infection. Antimicrob Agents Chemother 2014, 58:4885-4893.
24. Antivir Ther 2014, published online May 15. 10.3851/IMP2792.
25. Al-Tawfiq JA, Hinedi K, Ghandour J, et al. Middle East respiratory syndrome coronavirus: a case-control study of hospitalized patients. Clin Infect Dis 2014, 59:160-165.
26. Knowles SR, Phillips EJ, Dresser L, Matukas L Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada. Clin Infect Dis 2003, 37:1139-1142.
27. Sung JJ, Wu A, Joynt GM, et al. Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. Thorax 2004, 59:414-420.